This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adicet Bio, Inc. (ACET) been one of those stocks this year?

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

Gossamer Bio’s latest analyst update leaves the model fair value unchanged at US$4.46 per share and highlights an underweight stance, anchored by a sharply lower US$0.28 price target from some on the ...

While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...

Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Bluebird Bio has three approved gene-editing therapies: Zynteglo, Skysona, and Lyfgenia. The most important of this trio, and the latest to earn approval (it did so in December), is Lyfgenia, which ...

On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year ...